PledPharma and Solasia enter license agreement to develop and commercialize PledOx® in Asia
Stockholm, 2017-11-20 07:30 CET (GLOBE NEWSWIRE) --
Stockholm, Sweden / Tokyo, Japan, November 20th 2017 - PledPharma AB (“PledPharma”) (STO: PLED) and Solasia Pharma K.K. (“Solasia”) (TSE: 4597) today jointly announce that they have entered a license agreement pertaining to the clinical development and commercialization of PledOx® in Japan, China, Hong Kong, Macau, South Korea and Taiwan.
Under the terms of this agreement, PledPharma grants exclusive development and commercialization rights to PledOx® in the territories mentioned and Solasia will pay upfront, development, regulatory and sales milestones of up to ~USD 83 million (SEK 700 million)*. In addition, Solasia will pay industry standard royalty rates on sales applicable for a deal pertaining to an in-licensed asset in Phase III development. Solasia will also fully finance an expansion of the Phase III program to include Asian patients subject to regulatory consultations.
The license agreement is initially focused on the use of PledOx® as prevention of chemotherapy induced peripheral neuropathy in colorectal cancer patients. The agreement with Solasia facilitates an expansion of the recently announced global Phase III-program for PledOx® with Asian patients, subject to regulatory consultations, aiming to gain sufficient documentation for regulatory approvals in the major Asian markets. In addition, a Phase I study in Japanese and Caucasian Healthy Volunteers with focus on safety, tolerability and pharmacokinetics will be conducted. Following potential regulatory approvals, Solasia will be responsible for the commercialization of PledOx® in Japan, China, Hong Kong, Macau, South Korea, and Taiwan.
“We are very excited to announce our partnership with Solasia – an ideal partner during the development, regulatory process and commercialization of PledOx in this very important region. The collaboration will ensure an optimized expansion of the Phase III program to include Asian patients, aiming at further realising the global commercial potential of our drug candidate,” said Nicklas Westerholm, Chief Executive Officer and President, PledPharma.
“We are convinced that PledOx, as a novel first in class therapy, will play an important role in fulfilling the significant unmet medical need of preventing chemotherapy induced peripheral neuropathy. Solasia is ideally equipped to support PledPharma during the remaining clinical development and local regulatory processes in Japan, and to effectively launch the product in key Asian markets,” said Yoshihiro Arai, President and Chief Executive Officer, Solasia.
As PledPharma announced earlier in November, following interactions with the regulatory authorities, EMA and FDA, the company has finalized the design of the global Phase III program for the drug candidate PledOx®. The Phase III studies are anticipated to be initiated at the end of 2017 with top line results expected during 2020.
* The total value of upfront and milestone payments is up to JPY 9.3 billion. The amount given in USD and SEK is subject to exchange rate.
Invitation to corporate presentation
PledPharma will attend the Redeye Life Science Seminar on November 24 at 11:00 CET where PledPharma will provide a company update and an overview of the license agreement with Solasia. The event will be live streamed from Redeyes website www.redeye.se. After the event, the presentation will be available on PledPharma's website.
PledOx® is a “first in class” drug candidate developed to provide patients, that are treated adjuvantly or for metastatic colorectal cancer, prevention against the nerve damage that can occur in conjunction with chemotherapy treatment. The side-effects of chemotherapy can lead to a reduction of the planned dose or, in worst case, treatment discontinuation. Unfortunately, it appears that the chemotherapy can induce permanent nerve damage. Patients may, for example, experience discomfort and numbness in the hands and feet, difficulty with balance with risk of falling and problems with sensation that can last for the rest of their lives.
About chemotherapy induced peripheral neuropathy (CIPN)
Peripheral neuropathy symptoms are caused by damages to sensory nerves, most commonly in hands and feet. Certain chemotherapies, including oxaliplatin, can cause such damages, which is then called chemotherapy induced peripheral neuropathy (CIPN). This can be a debilitating adverse reaction of the cancer treatment and may occur at any time after the initiation of chemotherapy. The symptoms often increase as the chemotherapy treatment continues and may often causes discontinuation of the chemotherapy. In many patients, the symptoms are resolved after discontinuing the chemotherapy, but up to 20-30% of the patients have sustained symptoms such as numbness, tingling and pain in hands and feet. Patients with CIPN may have difficulties with fine motor skill, such as buttoning buttons, challenges using a computer key board and become hypersensitive to cold. The sensory loss in the feet’s may increase the risk of falls. There is currently no approved drug to prevent or treat CIPN.
Solasia is a specialty pharmaceutical company based in Asia, with a mission of "Better Medicine for a Brighter Tomorrow". In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient's healthy living and to provide treatment options for the healthcare providers. Additional information is available at http://www.solasia.co.jp/en/
PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A phase IIb study has been conducted and will serve as the basis for the continued development. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see http://www.pledpharma.se/
For further information, please contact:
Nicklas Westerholm, Chief Executive Officer, PledPharma AB
Tel. +46 73 354 20 62
Rie Toyoda, Investor Relations, Solasia Pharma K.K.
Tel. +81 3 6721 8332
This information is information that PledPharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CET on November 20, 2017
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
NEP GROUP RECOGNIZED AT THREE AWARDS SHOWS DURING IBC 201819.9.2018 16:17 | Pressemelding
Leading Outsourced Technical Production Partner Takes Home Top Honors at the SVG Europe Sport Production Awards, and was a Finalist for an IABM BaM™ Award 2018 and Two IBC2018 Innovation Awards PITTSBURGH and AMSTERDAM, Sept. 19, 2018 (GLOBE NEWSWIRE) -- NEP Group is thrilled to announce today that the company received recognition for their leading innovations, along with their client partners, at this year’s IBC Show. NEP The Netherlands’ Remote Commentary solution won the SVG Europe Sport Production Award for Outstanding Technical Achievement, Audio and was a finalist for an IABM BaM™ Award award for Project, Collaboration or Event. NEP’s Mediabank product was a finalist for an IBC2018 Innovation award for Content Distribution and NEP Finland was a finalist in the Content Everywhere category. “At NEP, one of our core values is client-driven innovation, and we are entirely committed to developing new technology that solves real-world challenges and delivers exceptional results. It’s w
Panini Hires Dan Napoles as Senior Vice President, Global Technical Services19.9.2018 14:36 | Pressemelding
Addition to Panini Executive Leadership Team DAYTON, Ohio, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Panini is pleased to announce that effective September 17, 2018, Dan Napoles joined the company as Senior Vice President, Global Technical Services (GTS) and will lead the company’s technical services functions worldwide including services delivery, services program definition & development, GTS commercial results & operational excellence, and GTS strategic direction & growth. Napoles will be instrumental to Panini’s strategy to support continued growth while extending its market leadership position. Mr. Napoles comes to Panini after a highly successful career in services with Avery Dennison, a $6.6 billion global materials science and manufacturing company with operations in more than 50 countries. During his tenure with Avery Dennison, Dan started as a field engineer in Los Angeles CA, servicing printers and radio frequency security systems, including system installation and contract sales r
Flashpoint Global Channel Program Welcomes New Talent to Accelerate Growth in EMEA Region19.9.2018 12:00 | Pressemelding
Appointment of Industry Veteran Reinforces Company’s Commitment to Partnerships, International Expansion NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Flashpoint, the global leader in Business Risk Intelligence (BRI), today announced that industry veteran Roy Pickard has joined the company as channel sales manager for Europe, the Middle East and Africa (EMEA). His appointment as the first EMEA-based member of the Flashpoint Global Channel Program (GCP) team marks the latest international milestone for the company, following its successful expansion in Asia Pacific and Latin America earlier this year. Pickard brings more than two decades of experience forging lasting partnerships and strengthening channel portfolios at esteemed security and technology enterprises including Resolve Systems, Tufin, Carbon Black, FireEye, Safenet Inc., and TrendMicro. At Flashpoint, he will lead recruitment, development, and enablement initiatives for channel partners throughout EMEA. Given the immense size
FOUR IN FIVE EXECUTIVES AGREE AGILITY IS MOST IMPORTANT CHARACTERISTIC OF A SUCCESSFUL ORGANIZATION18.9.2018 16:03 | Pressemelding
New research by Forbes Insights and sponsored by Scrum Alliance brings light to the “elusive” Agile enterprise Denver Colorado, Sept. 18, 2018 (GLOBE NEWSWIRE) -- PRESS RELEASE FOR IMMEDIATE RELEASE: MEDIA CONTACT: September 18, 2018 Heather Leigh, Public Relations Director 720-443-7314,firstname.lastname@example.org www.scrumalliance.org SEPTEMBER 18, 2018 – DENVER, CO – A new report by Forbes Insights finds 81 percent of respondents agree on the critical importance of agility when it comes to leading a successful organization. The report, “The Elusive Agile Enterprise,” was sponsored by Scrum Alliance, a Scrum certifying body and the largest professional association of Agile practitioners worldwide. In preparing the report, the Forbes Insights team surveyed more than 1,000 C-level executives worldwide, and also conducted one-on-one interviews with leaders of select “champion” organizations, including GEHealthcare, J. Walter Thompson Company, Nokia, Team WIKISPEED, Toyota Connected and Unis
Cloudian Joins iRODS Consortium18.9.2018 15:00 | Pressemelding
HyperStore Enterprise Object Storage Validated with iRODS Platform SAN MATEO, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Cloudian today announced the company has joined the iRODS Consortium, the foundation that leads development and support of the integrated Rule-Oriented Data System (iRODS). Testing for HyperStore enterprise object storage with iRODS is complete, and users may now deploy the combined solution where local workflows require cost-effective, exabyte-scalable storage and ease of integration. iRODS is free open source software for data discovery, workflow automation, secure collaboration and data virtualization used by research and business organizations around the globe. Easily deployed in an existing infrastructure, iRODS creates a unified namespace and a metadata catalog of all the data and users within the storage environment. With the iRODS rule engine framework, users can completely automate an organization’s data management policy. “We’re thrilled to be working with
Harbert European Growth Capital Announces Final Close18.9.2018 14:35 | Pressemelding
LONDON, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Harbert European Growth Capital (“HEGCF”), is pleased to announce the final close of its second fund (“Fund II”) at €215 million, a substantial increase over Harbert European Growth Capital Fund I (“Fund I”). HEGCF, which provides debt capital to fund growth opportunities across technology, life science and other innovative sectors attracted significant institutional capital, as well as numerous family office investors. “We are grateful for the support and trust that our existing and new investors have placed in us,” said David Bateman, Senior Managing Director and co-head of HEGCF. “The market opportunity remains strong with many companies across Europe seeking expansion funding of various forms,” notes Johan Kampe, Senior Managing Director and co-head of HEGCF. It has been a busy start with Fund II already having closed investments in 21 new companies since the first close in summer 2017. HECGF also continues to have follow on investing acti
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom